Suchergebnisse - "Schmid, Peter"

PubPharm (27)

1

Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer : A Secondary Analysis of a Randomized Clinical Trial

enthalten in: JAMA network open | 2023

von Takahashi, M. | Cortés, J. | Dent, R. | +17

2

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Rugo, H. | Bardia, A. | Marmé, F. | +15

CommentIn: Nat Rev Clin Oncol. 2023 Nov;20(11):734. - PMID 37684406

3

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT) : a randomised phase II study

enthalten in: Breast cancer research and treatment | 2023

von Oswald, A. | Symeonides, S. | Wheatley, D. | +16

4

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

enthalten in: The New England journal of medicine | 2022

von Schmid, P. | Cortes, J. | Dent, R. | +128

CommentIn: Nat Rev Clin Oncol. 2022 Apr;19(4):220. - PMID 35217781

5

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain) : a multicentre, randomised, open-label, non-comparative, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Pérez-García, J. | Gebhart, G. | Ruiz Borrego, M. | +20

CommentIn: Future Oncol. 2022 Oct;18(33):3677-3688. - PMID 36300423

6

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY) : An open-label, multicentre, single-arm, phase Ⅱ trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Pérez-García, J. | Llombart-Cussac, A. | G Cortés, M. | +16

7

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

enthalten in: The New England journal of medicine | 2021

von Bardia, A. | Hurvitz, S. | Tolaney, S. | +117

CommentIn: Nat Rev Clin Oncol. 2021 Jun;18(6):322. - PMID 33931767

8

TROPiCS-02 : A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

enthalten in: Future oncology (London, England) | 2020

von Rugo, H. | Bardia, A. | Tolaney, S. | +9

9

Pembrolizumab for Early Triple-Negative Breast Cancer

enthalten in: The New England journal of medicine | 2020

von Schmid, P. | Cortes, J. | Pusztai, L. | +119

CommentIn: Nat Rev Clin Oncol. 2020 Apr;17(4):196. - PMID 32127649

10

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

enthalten in: The New England journal of medicine | 2020

von Modi, S. | Saura, C. | Yamashita, T. | +99

CommentIn: Cancer Discov. 2020 Feb;10(2):167. - PMID 31843763